YS Biopharma Co LtdNASDAQ:YS
- LAST PRICE1.5000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.5000/ 38
- Ask / Lots1.5300/ 5
- Open / Previous Close1.4700 / 1.5000
- Day Range
- 52 Week Range
- Volume230,165
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | YS |
|---|---|---|
| 09:32 ET | 4674 | 1.48 |
| 09:36 ET | 8745 | 1.48 |
| 09:39 ET | 1150 | 1.48 |
| 09:41 ET | 573 | 1.489 |
| 09:43 ET | 480 | 1.4702 |
| 09:45 ET | 2000 | 1.4803 |
| 09:48 ET | 1500 | 1.48 |
| 09:52 ET | 1400 | 1.48 |
| 09:56 ET | 120 | 1.5 |
| 09:59 ET | 5250 | 1.4808 |
| 10:01 ET | 5036 | 1.49 |
| 10:03 ET | 1910 | 1.47 |
| 10:08 ET | 176 | 1.4733 |
| 10:10 ET | 4367 | 1.47 |
| 10:12 ET | 3425 | 1.46 |
| 10:15 ET | 2915 | 1.45 |
| 10:17 ET | 5614 | 1.44 |
| 10:19 ET | 2692 | 1.42 |
| 10:21 ET | 10412 | 1.42 |
| 10:24 ET | 2000 | 1.42 |
| 10:26 ET | 7450 | 1.47 |
| 10:33 ET | 724 | 1.4201 |
| 10:37 ET | 1333 | 1.43 |
| 10:39 ET | 300 | 1.45 |
| 10:42 ET | 150 | 1.46 |
| 10:50 ET | 976 | 1.4308 |
| 10:51 ET | 100 | 1.42 |
| 10:53 ET | 1000 | 1.4599 |
| 10:55 ET | 3848 | 1.4301 |
| 10:57 ET | 1352 | 1.43 |
| 11:00 ET | 2200 | 1.42 |
| 11:02 ET | 370 | 1.43 |
| 11:04 ET | 200 | 1.42 |
| 11:06 ET | 641 | 1.425 |
| 11:09 ET | 200 | 1.43 |
| 11:11 ET | 100 | 1.43 |
| 11:24 ET | 1250 | 1.4655 |
| 11:26 ET | 240 | 1.4201 |
| 11:27 ET | 100 | 1.4481 |
| 11:29 ET | 400 | 1.4227 |
| 11:31 ET | 200 | 1.42 |
| 11:38 ET | 200 | 1.43 |
| 12:02 ET | 100 | 1.4699 |
| 12:03 ET | 1000 | 1.432 |
| 12:05 ET | 100 | 1.44 |
| 12:09 ET | 3819 | 1.48 |
| 12:12 ET | 100 | 1.45 |
| 12:18 ET | 386 | 1.4552 |
| 12:21 ET | 1700 | 1.475 |
| 12:23 ET | 3298 | 1.4701 |
| 12:25 ET | 500 | 1.47 |
| 12:30 ET | 700 | 1.4797 |
| 12:36 ET | 100 | 1.47 |
| 12:38 ET | 300 | 1.48 |
| 12:41 ET | 500 | 1.47 |
| 12:43 ET | 200 | 1.46 |
| 12:45 ET | 200 | 1.46 |
| 12:48 ET | 600 | 1.4609 |
| 12:50 ET | 285 | 1.47 |
| 12:52 ET | 300 | 1.465 |
| 12:54 ET | 1312 | 1.46 |
| 12:57 ET | 350 | 1.46 |
| 12:59 ET | 3878 | 1.46 |
| 01:01 ET | 100 | 1.46 |
| 01:06 ET | 189 | 1.465 |
| 01:10 ET | 1000 | 1.465 |
| 01:21 ET | 199 | 1.4781 |
| 01:26 ET | 225 | 1.4735 |
| 01:46 ET | 5000 | 1.45 |
| 01:51 ET | 2000 | 1.4501 |
| 01:53 ET | 1513 | 1.4697 |
| 02:02 ET | 12100 | 1.48 |
| 02:08 ET | 772 | 1.4762 |
| 02:15 ET | 650 | 1.47 |
| 02:24 ET | 460 | 1.46 |
| 02:26 ET | 1500 | 1.48 |
| 02:29 ET | 11066 | 1.5 |
| 02:31 ET | 3604 | 1.4654 |
| 02:33 ET | 430 | 1.4999 |
| 02:36 ET | 7386 | 1.47 |
| 02:38 ET | 270 | 1.485 |
| 02:44 ET | 733 | 1.4999 |
| 02:45 ET | 10708 | 1.51 |
| 02:47 ET | 1000 | 1.51 |
| 02:49 ET | 400 | 1.5199 |
| 02:51 ET | 2394 | 1.52 |
| 02:54 ET | 5116 | 1.5499 |
| 02:56 ET | 7296 | 1.54 |
| 02:58 ET | 9992 | 1.5301 |
| 03:00 ET | 1434 | 1.53 |
| 03:03 ET | 600 | 1.53 |
| 03:05 ET | 1522 | 1.53 |
| 03:07 ET | 200 | 1.53 |
| 03:09 ET | 267 | 1.5344 |
| 03:12 ET | 144 | 1.5301 |
| 03:14 ET | 3839 | 1.53 |
| 03:16 ET | 100 | 1.5 |
May 16, 2023
YS Biopharma's PIKA Rabies Vaccine Gets Phase 3 Clinical Trial Approval in Pakistan, from 10:26AM ET on Tuesday May 16, 2023 by MT Newswires
10:26AM ET on Tuesday May 16, 2023 by MT NewswiresBRIEF-YS Biopharma Phase 3 Clinical Trial Will Evaluate Immunogenicity Of Co's Pika Rabies Vaccine , from 7:11AM ET on Tuesday May 16, 2023 by Thomson Reuters
7:11AM ET on Tuesday May 16, 2023 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
YS Biopharma Co Ltd | 139.6M | 2.2x | --- |
Greenwich Lifesciences Inc | 140.2M | -17.4x | --- |
INmune Bio Inc | 141.2M | -5.1x | --- |
Corvus Pharmaceuticals Inc | 143.9M | -3.5x | --- |
Bioatla Inc | 144.4M | -1.2x | --- |
Annexon Inc | 144.9M | -1.2x | --- |
Company Information
YS Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Contact Information
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $139.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 93.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.69 |
Book Value | $7.02 |
P/E Ratio | 2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
